Prevalence of HIV and HCV among injecting drug users in three selected WHO-EMRO countries: a meta-analysis
| Autor: | Frank Kiwanuka, Rajab Nazari, Shah Jahan Shayan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Drug
medicine.medical_specialty Injecting drug users media_common.quotation_subject Hepatitis C virus Human immunodeficiency virus (HIV) Medicine (miscellaneous) HIV Infections Review Hepacivirus Iran medicine.disease_cause World Health Organization Drug Users 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Prevalence Humans Pakistan 030212 general & internal medicine media_common Hepatitis business.industry Public Health Environmental and Occupational Health Afghanistan HIV Hepatitis C medicine.disease Psychiatry and Mental health Systematic review Meta-analysis Cohort 030211 gastroenterology & hepatology Public aspects of medicine RA1-1270 business |
| Zdroj: | Harm Reduction Journal Harm Reduction Journal, Vol 18, Iss 1, Pp 1-13 (2021) |
| ISSN: | 1477-7517 |
| Popis: | BackgroundHIV and Hepatitis C Virus (HCV) infections are responsible for a significant burden of mortality and morbidity, particularly in developing countries. This study sought to determine the prevalence of HIV and Hepatitis C among injecting drug users in Afghanistan, Iran, and Pakistan.MethodsThis review conforms to the Preferred Reporting Guidelines for Systematic Reviews and Meta-Analysis (PRISMA) statement. Databases including PubMed, Scopus, Web of Science/Knowledge, SID.ir, and MAGIRAN were searched. Studies that were published from 2003 up to 2018 were considered for analysis. Studies were screened for inclusion in duplicate, and also, that data were narratively synthesized.ResultsWe report on data from 79 articles. The total number of participants in studies that assessed the prevalence of HIV among injecting drug users included 68,926 participants, while those from studies that assessed HCV prevalence were 23,016 participants. Overall HIV and HCV prevalence among injecting drug users in the three selected countries were 9.1% (95% CI 6.9–12.0%) and 48.3% (95% CI 43.9–52.7%), respectively. Iran had the highest HIV prevalence of 11.0% among injectable drug users (95% CI 8.4–14.2%), while Afghanistan had the lowest HIV prevalence of 3.1% (95% CI 1.5–6.3%) among three selected countries. In Pakistan, the prevalence of HIV was 8.6% (95% CI 4.8–15.0%). Regarding HCV prevalence, Pakistan had the highest while Afghanistan had the lowest, 54.4% (95% CI 33.5–73.9%) and 37.3% (95% CI 35.2–39.4%), respectively. HCV prevalence in Iran was 47.7% (95% CI 43.4–52.0%).ConclusionInjecting drug users form a special cohort of persons at risk of HIV and Hepatitis C infections. The prevalence of HIV and Hepatitis noted from our findings is significantly high. Awareness of the grave risk of spreading HIV and Hepatitis C associated with sharing needles is recommended among this sub-group of drug users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink